Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19....

Descripción completa

Detalles Bibliográficos
Autores principales: Frankel, Arthur E., Reddy, Renuka, DeSuza, Kayla R., Deeb, Khaled, Carlin, Aaron F., Smith, Davey, Xie, Yushuang, Naik, Eknath, Silver, Richard T., Hasselbalch, Hans C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077319/
https://www.ncbi.nlm.nih.gov/pubmed/33936671
http://dx.doi.org/10.1002/ccr3.3997
_version_ 1783684859625996288
author Frankel, Arthur E.
Reddy, Renuka
DeSuza, Kayla R.
Deeb, Khaled
Carlin, Aaron F.
Smith, Davey
Xie, Yushuang
Naik, Eknath
Silver, Richard T.
Hasselbalch, Hans C.
author_facet Frankel, Arthur E.
Reddy, Renuka
DeSuza, Kayla R.
Deeb, Khaled
Carlin, Aaron F.
Smith, Davey
Xie, Yushuang
Naik, Eknath
Silver, Richard T.
Hasselbalch, Hans C.
author_sort Frankel, Arthur E.
collection PubMed
description An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19.
format Online
Article
Text
id pubmed-8077319
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80773192021-04-29 Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib Frankel, Arthur E. Reddy, Renuka DeSuza, Kayla R. Deeb, Khaled Carlin, Aaron F. Smith, Davey Xie, Yushuang Naik, Eknath Silver, Richard T. Hasselbalch, Hans C. Clin Case Rep Case Reports An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19. John Wiley and Sons Inc. 2021-03-07 /pmc/articles/PMC8077319/ /pubmed/33936671 http://dx.doi.org/10.1002/ccr3.3997 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Frankel, Arthur E.
Reddy, Renuka
DeSuza, Kayla R.
Deeb, Khaled
Carlin, Aaron F.
Smith, Davey
Xie, Yushuang
Naik, Eknath
Silver, Richard T.
Hasselbalch, Hans C.
Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
title Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
title_full Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
title_fullStr Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
title_full_unstemmed Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
title_short Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
title_sort response to pegylated interferon in a covid‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077319/
https://www.ncbi.nlm.nih.gov/pubmed/33936671
http://dx.doi.org/10.1002/ccr3.3997
work_keys_str_mv AT frankelarthure responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT reddyrenuka responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT desuzakaylar responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT deebkhaled responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT carlinaaronf responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT smithdavey responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT xieyushuang responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT naikeknath responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT silverrichardt responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib
AT hasselbalchhansc responsetopegylatedinterferoninacovid19positiveelderlywomanwithprimarymyelofibrosistreatedwithruxolitinib

Ejemplares similares